Burlington, VT, United States
Burlington, VT, United States

The University of Vermont and State Agricultural College, more commonly known as the University of Vermont or UVM, is a public research university and, after 1862, the U.S. state of Vermont's land-grant university. The University of Vermont is labeled one of the original "Public Ivies," a publicly funded university considered as providing a quality of education comparable to those of the Ivy League.Founded in 1791, UVM is among the oldest universities in the United States and the fifth college established in New England after Harvard, Yale, Dartmouth and Brown.The university's 451-acre campus is located in Burlington. Features of the UVM campus include the historic University Green, the Dudley H. Davis Center—the first student center in the nation to receive U.S. Green Building Council LEED Gold certification—the Fleming Museum of Art, and the Gutterson/Patrick athletic complex, home to UVM's Division I athletic teams. The largest hospital complex in Vermont, The University of Vermont Medical Center, has its primary facility adjacent to the UVM campus and is affiliated with the UVM College of Medicine. Wikipedia.

Time filter

Source Type

Catheters, systems, and related methods for optimized for mapping, minimizing, and treating cardiac fibrillation in a patient, including an array of at least one stacked electrode pair, each electrode pair including a first electrode and a second electrode, wherein each electrode pair is configured to be orthogonal to a surface of a cardiac tissue substrate, wherein each first electrode is in contact with the surface to record a first signal, and wherein each second electrode is separated from the first electrode by a distance which enables the second electrode to record a second signal, wherein the catheter is configured to obtain one or more measurements from at least a first signal and a second signal in response to electrical activity in the cardiac tissue substrate indicative of a number of electrical circuit cores and distribution of the electrical circuit cores for a duration across the cardiac tissue substrate.

University of Vermont | Date: 2016-10-21

The present invention generally relates to inhibitors of DUOX1. In some aspects, an inhibitor may be applied to a subject having or being at risk for asthma or other conditions. The inhibitor may be applied by various techniques, such as pulmonary or topical delivery. In some embodiments, the inhibitor may include a peptide or other moiety having a reactive electrophile. The reactive electrophile can target cysteine or other residues within DUOX1 to inhibit its activity, e.g., by covalently binding to the residue. Other non-limiting examples of suitable inhibitors include hydroxynonenal, curcumin, sulforaphane, cinnamaldehyde, dimethyl fumarate, or phenyl vinyl sulfonate. Other aspects of the invention are generally directed to methods of making or using such inhibitors, kits involving such inhibitors, devices or formulations containing such inhibitors, or the like.

University of Vermont | Date: 2017-01-11

Methods for diagnosing and treating conditions associated with life-threatening neurological complications are provided. The methods involve in some aspects the identification of oxLDL and LOX-1 as critical players in pregnant subjects and in some cases subjects having severe preeclampsia (early onset preeclampsia). Related products and kits are also provided.

Systems, apparatuses, and methods for generating hot gases based on catalyzation involving flowing catalyst. Catalysis occurs in a flow-type mixing catalyzation channel in which a liquid catalyst mixes with a liquid reactant flowing in a desired flow regime, such as a striated (laminar) flow regime or a slug flow regime. Devices such as micro-thrusters for satellite and other applications and hot gas generators for powering another device, such as an electrical generator, can be made using one or more flow-type mixing catalyzation channels.

University of Vermont | Date: 2014-12-05

The invention relates to methods and compositions for regulation of GSK3 activity. The invention provides phosphorylated GSK3 polypeptides and antibodies that recognize such polypeptides The invention further includes methods for treating disorders that are associated with elevated or reduced GSK3 activity.

Lewinter M.M.,University of Vermont
New England Journal of Medicine | Year: 2014

A previously healthy 25-year-old man presents with pleuritic pain in the left side of the chest of 3 hours' duration, radiating to the left trapezius ridge and relieved by sitting forward. On physical examination, he appears anxious. His pulse is 104 beats per minute and regular, his blood pressure is 125/80 mm Hg without a paradoxical pulse, and his temperature is 37.8°C. A three-component friction rub is auscultated along the left sternal border. An electrocardiogram (ECG) reveals ST-segment elevations in multiple leads, which are consistent with acute pericarditis. How should this case be managed?. Copyright © 2014 Massachusetts Medical Society.

Howe A.K.,University of Vermont
Current Opinion in Cell Biology | Year: 2011

Calcium (Ca 2+) and the cAMP-dependent protein kinase (PKA) are pleiotropic cellular regulators and both exert powerful, diverse effects on cytoskeletal dynamics, cell adhesion, and cell migration. Localization, by A-kinase-anchoring proteins (AKAPs), of PKA activity to the protrusive leading edge, integrins, and other regulators of cytoskeletal dynamics has emerged as an important facet of its role in cell migration. Additional recent work has firmly established the importance of Ca 2+ influx through mechanosensitive transient receptor potential (TRP) channels and through store-operated Ca 2+ entry (SOCE) in cell migration. Finally, there is considerable evidence showing that these mechanisms of Ca 2+ influx and PKA regulation intersect-and often interact-and thus may work in concert to translate complex extracellular cues into the intracellular biochemical anisotropy required for directional cell migration. © 2011 Elsevier Ltd.

Rincon M.,University of Vermont
Trends in Immunology | Year: 2012

The incidence and diversity of chronic inflammatory diseases is increasing worldwide. However, the complexity of clinical symptoms has made it difficult to develop therapies that provide a substantial improvement for extended periods of time in a wide range of patient groups. Thus, there is a need for new therapies that target inflammatory responses without compromising immune defense. Interleukin (IL)-6, one of the first identified cytokines, has recently been recognized as a potential target in inflammatory disease. Here, I discuss how this cytokine has evolved from being a marker of inflammation to a successful target to control inflammation. I will summarize the results from the recent clinical studies using IL-6 receptor blockade, and describe potential mechanisms by which IL-6 can contribute to the progression of inflammatory diseases. © 2012 Elsevier Ltd.

Lung diseases remain a significant and devastating cause of morbidity and mortality worldwide. In contrast to many other major diseases, lung diseases notably chronic obstructive pulmonary diseases (COPDs), including both asthma and emphysema, are increasing in prevalence and COPD is expected to become the third leading cause of disease mortality worldwide by 2020. New therapeutic options are desperately needed. A rapidly growing number of investigations of stem cells and cell therapies in lung biology and diseases as well as in ex vivo lung bioengineering have offered exciting new avenues for advancing knowledge of lung biology as well as providing novel potential therapeutic approaches for lung diseases. These initial observations have led to a growing exploration of endothelial progenitor cells and mesenchymal stem (stromal) cells in clinical trials of pulmonary hypertension and COPD with other clinical investigations planned. Ex vivo bioengineering of the trachea, larynx, diaphragm, and the lung itself with both biosynthetic constructs as well as decellularized tissues have been used to explore engineering both airway and vascular systems of the lung. Lung is thus a ripe organ for a variety of cell therapy and regenerative medicine approaches. Current state-of-the-art progress for each of the above areas will be presented as will discussion of current considerations for cell therapy-based clinical trials in lung diseases.© AlphaMed Press 2013.

Sansoz F.,University of Vermont
Nano Letters | Year: 2011

Surface faceting on sidewalls is ubiquitously observed during crystal growth of semiconductor nanowires. However, predicting the thermal transport characteristics of faceted nanowires relevant to thermoelectric applications remains challenging. Here, direct molecular dynamics simulations show that thermal conductivity is considerably reduced in crystalline 〈111〉 Si nanowires with periodic sawtooth faceting compared to nanowires of same size with smooth sidewalls. It is discovered that surface phonon scattering is particularly high with {100} facets, but less pronounced with {113} facets and remarkably low with {111} facets, which suggests a new means to optimize phonon dynamics for nanoscale thermoelectric devices. This anomaly is reconciled by showing that the contribution of each facet to surface phonons is due to diffuse scattering rather than to backward scattering. It is further shown that this property is not changed by addition of an amorphous shell to the crystalline core, similar to the structure of experimental nanowires. © 2011 American Chemical Society.

Loading University of Vermont collaborators
Loading University of Vermont collaborators